OXNARD, Calif. — July 8, 2020 — CURE Pharmaceutical, (OTC: CURR), an innovative drug delivery and development company, today announced that its 25,000 square foot manufacturing facility has earned NSF International, cGMP certification for the manufacture of dietary supplements. This certification is issued only after extensive material and facility analysis and gives suppliers, retailers, regulators and consumers assurance that products manufactured by CURE meet the highest standards for safety, quality, sustainability and performance.

The NSF cGMP certification for manufacturing facilities of dietary supplements enables manufacturers to become independently certified by NSF as complying with cGMP requirements as listed in Section 8 of NSF/ANSI Standard 173. These requirements are consistent with the published cGMP regulation for dietary supplements as defined in 21 CFR § 111, which is published by the U.S. Food & Drug Administration, or FDA.

“With the NSF-certified logo on wellness products developed and manufactured by CURE, consumers can be confident that our products meet strict standards for public health protection,” said Rob Davidson, CURE Pharmaceutical CEO. “Achieving the highest grade possible during NSF’s review is a testament to the high standards to which we hold our quality management processes and importantly, it brings us another step closer to successfully marketing CURE-developed products on a global scale.”

More About NSF International

NSF International is a Pan American Health Organization/World Health Organization Collaborating Center focused on ensuring public health, safety and environmental quality. The trusted NSF mark can be found on millions of consumer, commercial and industrial products, including bottled water, dietary supplements, food equipment, home water treatment products, home appliances, among others.

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. CURE’s delivery vehicles include CUREfilm®, an advanced oral dissolvable film; CUREpods™, a novel chewable liquid or solid delivery form; and CUREdrops™, an emulsion technology that can be incorporated into different dosage forms (film, tincture, beverages, etc.), among others. CURE’s clinical pipeline includes CUREfilm® Blue (sildenafil to treat erectile dysfunction), and CUREfilm®Canna (THC and CBD) each designed to optimize the pharmacokinetic profile of the medicine. Other OTC wellness products include Vitamin D, BCP Sleep, and Electrolytes. (Visit CURE’s catalog for the complete list.) As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, cGMP manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

Forward-Looking Statements

Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company’s judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


Ina McGuinness

Deanne Eagle